PDF(Pubmed)
Abstract：
BACKGROUND: In recent years, the research on the relationship between sarcopenia before and after the treatment of esophageal cancer, as well as its impact on prognosis of esophageal cancer, has increased rapidly, which has aroused people\'s attention to the disease of patients with esophageal cancer complicated with sarcopenia. This review examines the prevalence of sarcopenia in patients with esophageal cancer, as well as the relationship between sarcopenia (before and after surgery or chemotherapy) and prognosis in patients with esophageal cancer. Moreover, we summarized the potential pathogenesis of sarcopenia and pharmacologic and non-pharmacologic therapies.
METHODS: A narrative review was performed in PubMed and Web of Science using the keywords (\"esophageal cancer\" or \"esophageal neoplasm\" or \"neoplasm, esophageal\" or \"esophagus neoplasm\" or \"esophagus neoplasms\" or \"neoplasm, esophagus\" or \"neoplasms, esophagus\" or \"neoplasms, esophageal\" or \"cancer of esophagus\" or \"cancer of the esophagus\" or \"esophagus cancer\" or \"cancer, esophagus\" or \"cancers, esophagus\" or \"esophagus cancers\" or \"esophageal cancer\" or \"cancer, esophageal\" or \"cancers, esophageal\" or \"esophageal cancers\") and (\"sarcopenia\" or \"muscular atrophy\" or \"aging\" or \"senescence\" or \"biological aging\" or \"aging, biological\" or \"atrophies, muscular\" or \"atrophy, muscular\" or \"muscular atrophies\" or \"atrophy, muscle\" or \"atrophies, muscle\" or \"muscle atrophies\"). Studies reporting relationship between sarcopenia and esophageal cancer were analyzed.
RESULTS: The results of the review suggest that the average prevalence of sarcopenia in esophageal cancer was 46.3% ± 19.6% ranging from 14.4 to 81% and sarcopenia can be an important predictor of poor prognosis in patients with esophageal cancer. Patients with esophageal cancer can suffer from sarcopenia due to their nutritional deficiencies, reduced physical activity, chemotherapy, and the effects of certain inflammatory factors and pathways. When classic diagnostic values for sarcopenia such as skeletal muscle index (SMI) are not available clinically, it is also feasible to predict esophageal cancer prognosis using simpler metrics, such as calf circumference (CC), five-count sit-up test (5-CST), and six-minute walk distance (6MWD).
CONCLUSIONS: Identifying the potential mechanism of sarcopenia in patients with esophageal cancer and implementing appropriate interventions may hold the key to improving the prognosis of these patients.
METHODS: A narrative review was performed in PubMed and Web of Science using the keywords (\"esophageal cancer\" or \"esophageal neoplasm\" or \"neoplasm, esophageal\" or \"esophagus neoplasm\" or \"esophagus neoplasms\" or \"neoplasm, esophagus\" or \"neoplasms, esophagus\" or \"neoplasms, esophageal\" or \"cancer of esophagus\" or \"cancer of the esophagus\" or \"esophagus cancer\" or \"cancer, esophagus\" or \"cancers, esophagus\" or \"esophagus cancers\" or \"esophageal cancer\" or \"cancer, esophageal\" or \"cancers, esophageal\" or \"esophageal cancers\") and (\"sarcopenia\" or \"muscular atrophy\" or \"aging\" or \"senescence\" or \"biological aging\" or \"aging, biological\" or \"atrophies, muscular\" or \"atrophy, muscular\" or \"muscular atrophies\" or \"atrophy, muscle\" or \"atrophies, muscle\" or \"muscle atrophies\"). Studies reporting relationship between sarcopenia and esophageal cancer were analyzed.
RESULTS: The results of the review suggest that the average prevalence of sarcopenia in esophageal cancer was 46.3% ± 19.6% ranging from 14.4 to 81% and sarcopenia can be an important predictor of poor prognosis in patients with esophageal cancer. Patients with esophageal cancer can suffer from sarcopenia due to their nutritional deficiencies, reduced physical activity, chemotherapy, and the effects of certain inflammatory factors and pathways. When classic diagnostic values for sarcopenia such as skeletal muscle index (SMI) are not available clinically, it is also feasible to predict esophageal cancer prognosis using simpler metrics, such as calf circumference (CC), five-count sit-up test (5-CST), and six-minute walk distance (6MWD).
CONCLUSIONS: Identifying the potential mechanism of sarcopenia in patients with esophageal cancer and implementing appropriate interventions may hold the key to improving the prognosis of these patients.
摘要：
背景：近年来，食管癌治疗前后肌少症关系的研究,以及它对食管癌预后的影响，增长迅速，引起了人们对食管癌患者并发肌少症的关注。这篇综述探讨了食管癌患者中肌肉减少症的患病率。以及食管癌患者肌少症(手术或化疗前后)与预后的关系。此外，我们总结了肌肉减少症的潜在发病机制以及药物和非药物治疗。
方法：在PubMed和WebofScience中使用关键词（“食道癌”或“食道肿瘤”或“肿瘤，食管\"或\"食管肿瘤\"或\"食管肿瘤\"或\"肿瘤，食管\“或\”肿瘤，食管\“或\”肿瘤，“食道癌”或“食道癌”或“食道癌”或“食道癌”或“癌症”，食道癌，食道\"或\"食管癌\"或\"食管癌\"或\"癌症，食道癌或食道癌，食道\"或\"食管癌\")和(\"肌少症\"或\"肌肉萎缩\"或\"老化\"或\"衰老\"或\"生物老化\"或\"老化，生物\“或\”萎缩，肌肉萎缩，肌肉\"或\"肌肉萎缩\"或\"萎缩，肌肉“或”萎缩，肌肉\"或\"肌肉萎缩\")。分析报道的研究报告肌肉减少症与食管癌的关系。
结果：综述结果表明，食管癌中肌肉减少症的平均患病率为46.3%±19.6%，范围为14.4%～81%，肌肉减少症可以作为食管癌患者预后不良的重要预测指标。食道癌患者由于营养缺乏而可能患有肌肉减少症,减少体力活动，化疗,以及某些炎症因子和途径的影响。当临床上无法获得骨骼肌指数（SMI）等肌肉减少症的经典诊断值时，使用更简单的指标来预测食管癌的预后也是可行的，如小腿周长(CC)，五计数静坐测试（5-CST），和六分钟步行距离（6MWD）。
结论：明确食管癌患者肌少症的潜在机制并实施适当的干预措施可能是改善这些患者预后的关键。
方法：在PubMed和WebofScience中使用关键词（“食道癌”或“食道肿瘤”或“肿瘤，食管\"或\"食管肿瘤\"或\"食管肿瘤\"或\"肿瘤，食管\“或\”肿瘤，食管\“或\”肿瘤，“食道癌”或“食道癌”或“食道癌”或“食道癌”或“癌症”，食道癌，食道\"或\"食管癌\"或\"食管癌\"或\"癌症，食道癌或食道癌，食道\"或\"食管癌\")和(\"肌少症\"或\"肌肉萎缩\"或\"老化\"或\"衰老\"或\"生物老化\"或\"老化，生物\“或\”萎缩，肌肉萎缩，肌肉\"或\"肌肉萎缩\"或\"萎缩，肌肉“或”萎缩，肌肉\"或\"肌肉萎缩\")。分析报道的研究报告肌肉减少症与食管癌的关系。
结果：综述结果表明，食管癌中肌肉减少症的平均患病率为46.3%±19.6%，范围为14.4%～81%，肌肉减少症可以作为食管癌患者预后不良的重要预测指标。食道癌患者由于营养缺乏而可能患有肌肉减少症,减少体力活动，化疗,以及某些炎症因子和途径的影响。当临床上无法获得骨骼肌指数（SMI）等肌肉减少症的经典诊断值时，使用更简单的指标来预测食管癌的预后也是可行的，如小腿周长(CC)，五计数静坐测试（5-CST），和六分钟步行距离（6MWD）。
结论：明确食管癌患者肌少症的潜在机制并实施适当的干预措施可能是改善这些患者预后的关键。
